{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+Lung&page=12", "query": { "condition": "Adenocarcinoma Lung", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 910, "total_pages": 91, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+Lung&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adenocarcinoma+Lung&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T09:59:48.423Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03074513", "title": "Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Appendix Adenocarcinoma", "Human Papillomavirus-Related Anal Squamous Cell Carcinoma", "Human Papillomavirus-Related Cervical Squamous Cell Carcinoma", "Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis", "Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma", "Neuroendocrine Carcinoma", "Pancreatic Neuroendocrine Tumor", "Recurrent Merkel Cell Carcinoma", "Recurrent Nasopharynx Carcinoma", "Recurrent Peritoneal Malignant Mesothelioma", "Recurrent Pleural Malignant Mesothelioma", "Stage III Merkel Cell Carcinoma AJCC v7", "Stage III Nasopharyngeal Carcinoma AJCC v7", "Stage III Pleural Malignant Mesothelioma AJCC v7", "Stage IV Merkel Cell Carcinoma AJCC v7", "Stage IV Nasopharyngeal Carcinoma AJCC v7", "Stage IV Pleural Malignant Mesothelioma AJCC v7", "Stage IVA Nasopharyngeal Carcinoma AJCC v7", "Stage IVB Nasopharyngeal Carcinoma AJCC v7", "Stage IVC Nasopharyngeal Carcinoma AJCC v7", "Vaginal Squamous Cell Carcinoma, Not Otherwise Specified" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 133, "start_date": "2017-03-03", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-14T09:59:48.423Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03074513" }, { "nct_id": "NCT07020117", "title": "A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urothelial Carcinoma Bladder", "Triple Negative Breast Cancer (TNBC)", "Hormone Receptor Positive Breast Adenocarcinoma", "Non Small Cell Lung Cancer", "Cervical Adenocarcinoma", "Colorectal Adenocarcinoma", "Head and Neck Cancer" ], "interventions": [ { "name": "[225Ac]Ac-AKY-1189 (therapeutic)", "type": "DRUG" }, { "name": "[64Cu]Cu-AKY-1189 (imaging)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aktis Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2025-08-22", "completion_date": "2032-06", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-14T09:59:48.423Z", "location_count": 14, "location_summary": "Duarte, California • Irvine, California • Miami, Florida + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07020117" }, { "nct_id": "NCT03652077", "title": "A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cervical Cancer", "Gastric Cancer", "Stomach Cancer", "Gastroesophageal Junction Cancer", "Esophageal Cancer", "Hepatocellular Carcinoma", "Melanoma", "Uveal Melanoma", "Merkel Cell Carcinoma", "Mesothelioma", "MSI", "Non-small Cell Lung Cancer", "NSCLC", "Ovarian Cancer", "Squamous Cell Carcinoma of the Head and Neck", "Small Cell Lung Cancer", "Renal Cell Carcinoma", "RCC", "Triple-negative Breast Cancer", "Urothelial Carcinoma", "Mismatch Repair Deficiency" ], "interventions": [ { "name": "INCAGN02390", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2018-09-24", "completion_date": "2021-08-18", "has_results": false, "last_update_posted_date": "2021-11-15", "last_synced_at": "2026-10-14T09:59:48.423Z", "location_count": 4, "location_summary": "Los Angeles, California • Jackson, Mississippi • Hackensack, New Jersey + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jackson", "state": "Mississippi" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Huntsville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03652077" }, { "nct_id": "NCT05064150", "title": "Neuroendocrine Tumors - Patient Reported Outcomes", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neuroendocrine Tumors", "Gastroenteropancreatic Neuroendocrine Tumor", "Lung Neuroendocrine Neoplasm", "Neuroendocrine Carcinoma" ], "interventions": [], "intervention_types": [], "sponsor": "University of Iowa", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2539, "start_date": "2022-05-10", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-14T09:59:48.423Z", "location_count": 14, "location_summary": "Gainesville, Florida • Iowa City, Iowa • Kansas City, Kansas + 11 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05064150" }, { "nct_id": "NCT00776100", "title": "Radiation Therapy or Observation After Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "clinical observation", "type": "OTHER" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "OTHER", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 3, "start_date": "2008-10", "completion_date": "2010-09", "has_results": true, "last_update_posted_date": "2017-03-06", "last_synced_at": "2026-10-14T09:59:48.423Z", "location_count": 168, "location_summary": "Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 103 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Bloomington", "state": "Illinois" }, { "city": "Canton", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00776100" }, { "nct_id": "NCT02134912", "title": "S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of the Lung", "Large Cell Lung Cancer", "Recurrent Non-small Cell Lung Cancer", "Stage IV Non-small Cell Lung Cancer" ], "interventions": [ { "name": "crizotinib", "type": "DRUG" }, { "name": "pemetrexed disodium", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2014-08", "completion_date": "2016-09", "has_results": true, "last_update_posted_date": "2020-02-20", "last_synced_at": "2026-10-14T09:59:48.423Z", "location_count": 167, "location_summary": "Sacramento, California • Aurora, Colorado • Colorado Springs, Colorado + 111 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Fort Collins", "state": "Colorado" }, { "city": "Hartford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02134912" }, { "nct_id": "NCT07124000", "title": "DESTINY-PANTUMOUR04", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adenocarcinoma (NOS)", "Anal Cancer", "Bladder Cancer", "Cervical Cancer", "Endometrial Cancer", "Esophageal Cancer", "Gall Bladder Cancer", "Gastrointestinal Stromal Tumour", "Head and Neck Cancer", "Liver Cancer", "Melanoma", "Mouth Cancer", "Nasopharangeal Cancer", "Neuroendocrine, Gastrointestinal Cancer", "Ovarian Cancer", "Pancreatic Cancer", "Prostate Cancer", "Renal Cell Carcinoma", "Salivary Gland Cancer", "Sarcoma", "Small Cell Lung Cancer", "Testicular Cancer", "Throat Cancer", "Thyroid Cancer", "Urethral Cancer", "Vaginal Cancer", "Vulvar Cancer" ], "interventions": [ { "name": "Trastuzumab deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 100, "start_date": "2025-09-18", "completion_date": "2028-03-30", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-14T09:59:48.423Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Bullhead City, Arizona • Casa Grande, Arizona + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Bullhead City", "state": "Arizona" }, { "city": "Casa Grande", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Boulder", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07124000" }, { "nct_id": "NCT07166601", "title": "M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "M0324", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "mFOLFIRINOX", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "EMD Serono Research & Development Institute, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2025-10-10", "completion_date": "2029-02-23", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-14T09:59:48.423Z", "location_count": 3, "location_summary": "New Haven, Connecticut • New York, New York • San Antonio, Texas", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "New York", "state": "New York" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07166601" }, { "nct_id": "NCT04902040", "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Bladder Carcinoma", "Advanced Lung Non-Small Cell Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Melanoma", "Advanced Merkel Cell Carcinoma", "Advanced Renal Cell Carcinoma", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III Merkel Cell Carcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV Merkel Cell Carcinoma AJCC v8", "Pathologic Stage III Cutaneous Melanoma AJCC v8", "Pathologic Stage III Merkel Cell Carcinoma AJCC v8", "Pathologic Stage IIIA Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8", "Pathologic Stage IIIB Cutaneous Melanoma AJCC v8", "Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Cutaneous Melanoma AJCC v8", "Pathologic Stage IV Merkel Cell Carcinoma AJCC v8", "Stage III Bladder Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IIIA Bladder Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Bladder Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVA Bladder Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Bladder Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Plinabulin", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2021-04-14", "completion_date": "2025-02-27", "has_results": true, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-10-14T09:59:48.423Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04902040" }, { "nct_id": "NCT02250885", "title": "KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Neuroendocrine" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gabrail Cancer Center Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2014-08", "completion_date": "2016-08", "has_results": false, "last_update_posted_date": "2019-09-17", "last_synced_at": "2026-10-14T09:59:48.423Z", "location_count": 1, "location_summary": "Canton, Ohio", "locations": [ { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02250885" } ] }